AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Mirum Pharmaceuticals to Present at Evercore ISI 2nd Annual HealthCONx Conference

November 25, 2019

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov 25, 2019--

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that company management will participate at the Evercore ISI 2 nd Annual HealthCONx Conference.

A live audio webcast and archive of the presentation will be available at http://ir.mirumpharma.com

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS). For more information, visit MirumPharma.com. Follow Mirum on Twitter, Facebook and LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191125005078/en/

CONTACT: Media Contact:

Heidi Chokeir, Ph.D.

Canale Communications

619-203-5391

heidi@canalecomm.com Investor Contact:

Ian Clements, Ph.D.

650-667-4085

ir@mirumpharma.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS

SOURCE: Mirum Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 11/25/2019 08:30 AM/DISC: 11/25/2019 08:30 AM

http://www.businesswire.com/news/home/20191125005078/en